2025年 11月5日至10日 ， 第八届中国国际进口博览会（CIIE 2025） 在上海国家会展中心举行。来自全球100多个国家和地区的2800余家企业齐聚申 城，其中，医疗器械及医药保健展区再次成为创新"首发"高地。 据思宇MedTech观察，今年的进博会在医疗科技领域呈现三大特征： 全球创新密度更高、系统协同趋势更强、国产厂商参与更深。 从AI影像、介入治疗、 手术机器人到生命支持系统与康复设备，一批"全球首发""中国首展""概念验证"级产品集中亮相，构成了新一轮全球医疗技术演进的样本。 思宇特别盘点本届进博会中值得关注的 19家核心企业 ——从波士顿科学、美敦力、 爱尔康 ，到GE、西门子、 直观复星 与元化智能，覆盖影像诊疗、智能 手术、 眼科创新、 生命支持、心血管与康复全链条 ， 带你一文看尽2025进博会的医疗科技"首发矩阵"。 图源：视觉中国 # 波士顿科学： 多管 线集结，微 创与智能双线升 级 在第八届中国国际进口博览会上，波士顿科学以"为生命创新，共进致远"为主题，携 80 余款微创介入产品重磅亮相，六款新品迎来"首展首秀"。它们分别 是： FARAWAVE NAV 一次性使用磁定位心 ...

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Jinxin Reproductive Medicine (01951.HK) by 7.45 million shares on November 3, 2025, marking a decrease of 0.52% [1][2] - Over the past five trading days, there have been four days of net reductions in holdings, totaling 8.89 million shares [1][2] - In the last 20 trading days, there were 11 days of net increases in holdings, amounting to a total of 15.63 million shares [1][2] Group 2 - As of now, southbound funds hold 1.436 billion shares of Jinxin Reproductive Medicine, which represents 52.07% of the company's total issued ordinary shares [1][2] - Jinxin Reproductive Medicine is an investment holding company primarily providing in vitro fertilization (IVF) services, along with various reproductive and medical services [2] - The company operates mainly in China and the United States, offering auxiliary reproductive services, management services, and sales of medical consumables and equipment [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 錦欣生殖醫療集團有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01951 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊 ...

Core Insights - The China International Import Expo (CIIE) serves as a vital platform for global innovation to enter the Chinese market, with companies like Edwards Lifesciences leveraging it to enhance local partnerships and accelerate the clinical application of innovative medical technologies [1][2] - Edwards has witnessed significant growth in the Chinese medical industry over the past 25 years, benefiting from an improved business environment and innovative regulatory breakthroughs [1] - The company plans to expand its local collaboration network and deepen partnerships with clinical experts to enhance the treatment of structural heart diseases in China [1] Company Highlights - Edwards Lifesciences has successfully transitioned multiple innovative products from exhibition to clinical application, including the INSPIRIS RESILIA valve launched in 2021 and the SAPIEN3 Ultra RESILIA valve, which debuted at the 2023 CIIE [1] - The MITRIS RESILIA valve was officially launched in China in April 2023, showcasing the rapid commercialization of products introduced at the expo [1] - The PASCAL Precision transcatheter valve repair system made its debut at the CIIE after being launched in Hong Kong [1] Other Company Activities - This year marks the sixth consecutive participation of Edwards at the CIIE, where it showcases a full range of cutting-edge products and treatment solutions, including an interactive experience area for participants [2] - AstraZeneca, Novo Nordisk, and Intuitive Surgical are also notable participants, with AstraZeneca planning to announce a new production expansion plan and showcasing over 40 innovative drugs [2] - Novo Nordisk is focusing on obesity management with an immersive experience space, highlighting the importance of public awareness regarding obesity [2] Product Innovations - Novo Nordisk will present advancements in its "semaglutide family" of products, including the approval of new indications for chronic kidney disease and the introduction of oral formulations [3] - Intuitive Surgical will showcase its da Vinci surgical robots, emphasizing its commitment to innovation in medical technology and the Chinese market [3] - The company aims to build a comprehensive training system for hospitals and doctors to enhance their skills in robotic surgery [3]

Core Points - Jinxin Fertility (01951) announced the resignation of Ms. Zhai Yangyang as co-company secretary and Ms. Wu Xiuwai as co-company secretary and authorized representative under the Hong Kong Stock Exchange Listing Rules effective October 31, 2025 [1] - Ms. Zhai resigned to pursue personal career development, while Ms. Wu resigned due to other work arrangements [1] - Ms. Zhong Manna has been appointed as the company secretary and authorized representative effective October 31, 2025 [1]

Core Points - Jinxin Fertility (01951) announced the resignation of two co-secretaries, Zhai Yangyang and Wu Xiuwai, effective October 31, 2025 [1] - Zhai Yangyang resigned to pursue personal career development, while Wu Xiuwai resigned due to other work arrangements [1] - Zhong Manna has been appointed as the new company secretary and authorized representative effective October 31, 2025 [1]

Core Viewpoint - Jinxin Reproductive (01951.HK) announced the resignation of two co-secretaries and the appointment of a new company secretary effective October 31, 2025 [1] Group 1 - Zhai Yangyang resigned as co-secretary for personal career development reasons [1] - Wu Xiuwai resigned as co-secretary and authorized representative due to other work arrangements [1] - Zhong Manna has been appointed as the new company secretary and authorized representative, bringing over 25 years of experience in corporate governance and compliance [1]

聯席公司秘書及授權代表變更 錦欣生殖醫療集團有限公司*（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，自2025年 10月31日起，翟揚揚女士（「翟女士」）已辭任本公司聯席公司秘書，及伍秀薇女士（「伍女 士」）已辭任本公司聯席公司秘書及香港聯合交易所有限公司（「聯交所」）證券上市規則第 3.05條項下之本公司授權代表（「授權代表」）。翟女士因追求其個人職業發展而辭任，伍女 士則因其他工作安排而辭任。 董事會謹此進一步宣佈，鍾曼娜女士（「鍾女士」）已自2025年10月31日起獲委任為本公司 的公司秘書及授權代表。鍾女士為達盟香港有限公司之公司秘書服務部主管，負責向客 戶提供公司秘書及合規服務。彼於公司秘書領域擁有超過25年經驗，對企業管治及合規 事務具豐富的知識及經驗。彼為香港公司治理公會及英國特許公司治理公會會員。 翟女士及伍女士均已確認，彼等與董事會並無意見分歧，亦無有關彼等辭任之事宜須敦 請聯交所及本公司股東垂注。 - 1 - 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 所產生或因依賴該 ...

Group 1 - The core point of the news is that southbound funds have reduced their holdings in Jinxin Fertility (01951.HK) by 1.742 million shares on October 27, 2025, while there have been net increases in holdings on 3 out of the last 5 trading days, totaling a net increase of 1.876 million shares [1] - Over the last 20 trading days, Jinxin Fertility has seen net increases in holdings for 13 days, with a total net increase of 23.729 million shares [1] - As of now, southbound funds hold 1.443 billion shares of Jinxin Fertility, accounting for 52.33% of the company's total issued ordinary shares [1] Group 2 - Jinxin Fertility Medical Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers assisted reproductive services, management services, mobile surgical center facility services, auxiliary medical services, obstetrics and pediatrics medical services, as well as sales of medical consumables and equipment [2] - Jinxin Fertility operates mainly in China and the United States [2]

Core Viewpoint - Southbound funds have significantly increased their holdings in Jinxin Reproductive Medicine (01951.HK), indicating strong investor interest and confidence in the company’s performance and growth potential [1][2]. Group 1: Shareholding Changes - On October 24, southbound funds increased their holdings by 3.651 million shares, representing a 0.25% change [2]. - Over the past five trading days, there were four days of net increases, totaling 3.666 million shares [1]. - In the last 20 trading days, there were 14 days of net increases, amounting to 36.725 million shares [1]. Group 2: Current Shareholding Status - As of October 24, southbound funds hold a total of 1.445 billion shares of Jinxin Reproductive Medicine, which constitutes 52.39% of the company's total issued ordinary shares [1][2]. Group 3: Company Overview - Jinxin Reproductive Medicine is an investment holding company primarily providing in vitro fertilization (IVF) services [2]. - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and sales of medical consumables and equipment [2]. - The company operates mainly in China and the United States [2].